Remote monitoring improved glycemic control in children with type 1 diabetes

Intensive remote therapy (IRT) was able to improve blood glucose control in pediatric patients with type 1 diabetes, according to a study published Feb. 21 in Pediatric Diabetes.

Continual communication between type 1 diabetes patients and care providers is key in maintaining glycemic control, but routine in-person visits can strain a patient. In response, researchers from Children’s Minnesota and UnitedHealth Group Research & Development aimed to provide insight into the potential benefits of IRT in pediatric patients with type 1 diabetes.

The study included 117 pediatric patients with type 1 diabetes, of which 60 received IRT while the remaining 57 received conventional care. During the six months of the study, both groups continued quality clinic visits and uploaded data collected from their diabetes devices. The IRT group’s data was received, and patients were contacted with changes in care needed to be made. Measures of blood glucose control and diabetes-related quality of life were included in the findings.

Results found the IRT group experience increased glycemic control after six months by reducing glycated hemoglobin by 0.34, compared to the 0.05 in the conventional care group. Broken down, children ages 8 to 12 in the IRT group reduced their glycated hemoglobin by 0.15 while the conventional care group saw a 0.02 reduction. Children ages 13 to 17 in the IRT group saw a 0.50 reduction, compared to a 0.06 reducing in the conventional care group. Additionally, diabetes-related quality of life increased by 6.5 points in the IRT group, compared to 1.3 points in the conventional care group. In the three months following the intervention, glycated hemoglobin changed minimally in children aged 8 to 12 but increased by 0.22 in children aged 13 to 17.

 “IRT substantially affected diabetes metrics and improved quality of life among pediatric patients with T1D,” wrote first author Laura Gandrud, of Children's Minnesota, and colleagues. “Adolescents experienced a stronger treatment effect, but had difficulty in sustaining improved control after intervention cessation.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.